Prelude Therapeutics

NEWARK, DE · Founded 2016 · CIK 0001678660 · Biotech · Private

Selective small-molecule degraders and inhibitors targeting cancer-driving proteins

preludetx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$97M
4 Form D · Aug 2020
73 months since last filing
Contracts
—
No federal contracts on record
Patents
40
8 granted · 32 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,000,000
Private capital raisedForm D · SEC$12,000,000
Private capital raisedForm D · SEC$29,999,999
Private capital raisedForm D · SEC$49,999,969
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2830JUNIPERO THERAPEUTICS, INC.——
2831Inceptive Nucleics, Inc.—$100M
2832Arena Pharmaceuticals—$187M
2833Prelude Therapeutics—$97M
2834Coriell Life Sciences, Inc.—$10M
2835Tango Therapeutics—$95M
2836Arcutis Biotherapeutics, Inc.—$94M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 13 related persons
  • David BonitaDirector
  • Andrew CombsExecutive Officer
  • Mardi DierDirector
  • Paul FriedmanDirector
  • Juan LuengoExecutive Officer
  • David MauroExecutive Officer
  • Deborah MorosiniExecutive Officer
  • Kelvin NeuDirector
  • Christopher PierceExecutive Officer
  • Brian PiperExecutive Officer
  • Victor SandorDirector
  • Peggy ScherleExecutive Officer
  • Krishna VaddiDirector · Executive Officer

Patents

USPTO · 8 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.